Objective. Observational data facilitate examination of treatment-effect heterogeneity, but the risk of bias is substantial. We highlight methodological considerations through an analysis of whether smoking affects response to TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA).
Introduction
Disease registries are important resources for observational research. They provide high quality data for large numbers of patients generalisable to clinical practice, making them invaluable for comparing effectiveness of treatments. However, observational data are susceptible to bias, requiring rigorous methodological approaches when attempting to infer causation. Consider the effect of smoking on response to TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA): an important clinical question since only half of patients respond (1, 2) and alternative treatment options are relatively limited. While some smaller studies reported that smoking did not have an important impact on TNFi response (3) (4) (5) , others found apparently dramatic effect sizes with current smokers having half the odds of response compared to non-smokers (6, 7) .
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Several methodological differences may explain these conflicting results. First, many patient characteristics differ according to smoking status (3, 6, 7) . Baseline disease severity is known to predict response to TNFi and should be adequately accounted for. Second, longitudinal studies apply selection criteria that typically exclude a proportion of participants from the analysis set, for example by requiring at least one follow-up visit. Such sample-restriction introduces selection bias if included and excluded participants differ in smoking status and other baseline characteristics. Third, continuation of TNFi typically requires demonstration of response, with variable enforcement and response definitions in different healthcare systems. Ongoing treatment in the UK is only funded if response is demonstrated at 12 weeks (allowing for some flexibility) as measured by the Bath AS Disease Activity Index (BASDAI) and spinal pain (8, 9) . Dropout due to inefficacy or adverse events are examples of non-random censoring (ie. these events are associated with participant characteristics) that can present problems for observational analyses (10) .
The aim of the current analyses was to examine the impact of smoking on response to TNFi in axSpA participants, while exploring common methodological issues and their solutions. We synthesise our discussion alongside a qualitative review of methods and results from existing studies.
Methods

Study design and population
The British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) is a UK-wide prospective cohort study of participants fulfilling the ASAS criteria for axSpA. The study protocol has been previously published (11) . The current analysis focused on those who started their first TNFi, from December 2012 to June 2017. These participants were followed up at baseline, 3, 6 and 12 months and annually thereafter, at study visits and using postal questionnaires. Start and stop dates were recorded for each TNFi, along with the reason for stopping (adverse events, inefficacy or other reasons). The cohort was defined at baseline, therefore only those with a valid baseline questionnaire (within 1 year before and 7 days after starting TNFi) and had smoking status were eligible for analysis. Where there was more than one questionnaire in each time period, the nearest one to the per-protocol follow-up time was chosen. Ethical approval was obtained from the National Research Ethics Committee (reference 11/NE/0374) and informed consent was obtained from all participants.
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Exposure and outcomes
Smoking status was self-reported as current, ex-or never in each questionnaire. Baseline smoking status was used to define the exposure; where this was missing, the earliest reported instance was used. Ex-smokers were defined as those who have not smoked for the past 3 months.
Outcomes included patient-reported disease activity (Bath AS Disease Activity Index (BASDAI), spinal pain), functional impairment (BASFI) and other aspects of disease severity such as the Bath AS Global Score (BASG), Chalder Fatigue Scale (12), Jenkins Sleep Evaluation Questionnaire (13) and the Hospital Anxiety and Depression Scale (HADS) (14) . The AS Disease Activity Score (ASDAS) was calculated using CRP or, if unavailable, ESR.
We compared changes in outcomes (measured by the above scales) over time to their pre-treatment baseline, between difference categories of smokers. To allow comparison with existing studies, we also compared proportions meeting a binary response, BASDAI50/2 (50% or 2-unit reduction in BASDAI) at 3, 6 and 12 months.
Covariates
The following covariates were recorded at baseline and chosen a priori for their known or theoretical associations with TNFi response (1, 2, (15) (16) (17) : age, gender, symptom duration, education, elevated baseline CRP (above upper normal limit), classification as AS (modified New York criteria (18)), HLA-B27 status, body mass index (BMI), index of multiple deprivation (in quintiles (19) (20) (21) ) as a measure of socioeconomic status, alcohol status (as current, ex-or never) and comorbidity (categorised as 0, 1 or ≥2 from 13 conditions (11)). Time was categorised by per-protocol follow-up.
Statistical analysis
Baseline participant characteristics were summarised by smoking status. For each outcome variable, we compared its change over time according to smoking status using generalised estimating equations (GEE) (22). This was achieved using interaction terms between smoking status and the time variable: their coefficients are interpreted as the difference in response compared to the reference group (never smokers). Model predictions were plotted to visualise results. These models were weighted with weights constructed as follows.
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We balanced differences in baseline characteristics between smoking exposure categories using inverse probability of "treatment" weights (IPTW) (23) . This adjustment approach has an advantage over inclusion of the baseline characteristics in the outcome model (the theoretical basis is given in supplementary materials). A multinomial logistic model was used to construct IPTW for each smoking category. Independent variables for the weight model included all baseline covariates specified above as well as all baseline outcome measures (as a collective representation of disease severity). Studying the causal effect of baseline smoking status has conceptual difficulty: we cannot randomly assign an individual to "having smoked for 20 years" at the onset of a hypothetical trial (24) . However, propensity score related methods are still useful for "unconfounded descriptive comparisons" (25, 26) .
Including participants with a baseline questionnaire assumes this selected subset is representative of the initial cohort. We improved upon this approach by weighting individuals in such a way that baseline characteristics of the analysis set resembles the original eligible cohort. This is a form of inverse probability of censoring weights (IPCW) for censoring at the baseline. IPCWs were constructed from predicted values of logistic models using inclusion/exclusion status as the dependent variable, and smoking status and available baseline covariates as independent variables.
To address informative censoring after the baseline, we first limited the above analysis to response within 3 months (analysis 1), during which time dropout due to inefficacy should be minimal. Missing 3-month responses were modelled using time-varying IPCWs as described above with "missingness" as the dependent variable. This makes missingness random with respect to baseline characteristics.
We then repeated the analysis for the subset of participants that remained on treatment from 6 months onwards (analysis 2) using baseline IPCWs to account for the excluded, as described above, but without additional use of time-varying IPCWs.
Lastly, BASDAI50/2 was used as the outcome in weighted logistic models. Dropout due to inefficacy was defined as non-response; other missing responses were modelled using IPCWs as described above. All weights were "stabilised" to have a mean of 1, allowing the overall sample size to remain unchanged (27) . Missing covariates were imputed using chained equations (see supplement for details) (28) . Analyses were performed in Stata version 13.
Results
Among a total of 2,420 participants in the BSRBR-AS, 840 commenced their first TNFi within the study period and provided smoking status. 213 participants were excluded because they did not have a valid baseline assessment. 627 participants were included in analyses, providing 1,641
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Analysis 1: Comparing response at 3 months according to smoking status
Baseline characteristics of the analysis cohort are shown in table 1. Covariate were well balanced after IP weighting (supplementary figure 1). A third of participants were current smokers, 30% exsmokers and 37% never smokers. Current smokers were younger, more frequently male and showed trends for having higher deprivation and lower educational attainment. Baseline values of most outcome variables were worse in ex-and current smokers. 218 participants had missing outcome measures at 3 months and were modelled using IPCWs; the number of participants who stopped their TNFi during this period was too small (n=1) to model separately.
All outcomes improved significantly after commencing TNFi. These changes were highly similar for each smoking status (BASDAI and BASFI shown in figure 1, remainder shown in supplementary figure 2). Although not statistically significant, interaction term coefficients suggest that BASDAI reduction at 3 months was greater for ex-(β= -0.58; 95%CI -1.41 to 0.25) and current smokers (β= -0.38; 95%CI-1.12 to 0.36) compared to never smokers (table 2) . Results were similar for most other outcome measures, except ex-smokers had significantly greater improvement in fatigue. Progression of outcome measures after 6 months were similar between each smoking status (table   3 ). Compared to never smokers, BASDAI increased by 0.07 units more (95%CI -0.11 to 0.24) for exsmokers and 0.04 units more (95%CI -0.13 to 0.22) for current smokers, per 6-month period. The only statistically significant differences were for fatigue and ASDAS. The slope coefficients suggest that current smokers may have poorer sustained treatment response after 6 months than never smokers ( figure 2 and supplementary figure 3 ).
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Results were similar at 6 months (ex-smokers: OR 1.01, 95%CI 0.67 to 1.50; current smokers: OR 0.85, 95%CI 0.56 to 1.27). At 12 months, ex-smokers had higher odds of response (OR 1.65, 95%CI
1.11 to 2.45), but not current smokers (OR 1.12, 95%CI 0.74 to 1.77). Distributions of all IP weights are described in supplementary table 3.
Discussion
In this large UK cohort of axSpA participants, baseline smoking status was associated with significantly worse disease severity at baseline across all measures. However, it was not associated with response to the first TNFi. This applied to all outcome measures including disease activity, functional impairment, quality of life, fatigue, sleep and mental health. We demonstrated the importance of several methodological considerations for future studies of non-interventional exposures on treatment response, and offer inverse-probability weighting as a solution to reduce potential bias.
The main strength of this study is the quality of data. Several outcomes were measured that provide a holistic representation of disease severity and impact. The rich BSRBR-AS dataset also allowed us to adjust for a large number of confounders, minimising the impact of unmeasured confounding.
Participants were recruited from both specialist and non-specialist secondary care centres, thus providing a relatively unselected population representative of UK clinical practice.
Our data did have some limitations. There was an unusually low proportion of discontinuation due to inefficacy, likely reflecting limitations in the way discontinuation reasons were labelled. However, the start and stop dates for each TNFi were diligently recorded, providing clear information about duration of use. The BSRBR-AS did not record exercise or other lifestyle factors that are potential confounders. We did adjust for socioeconomic status, and included alcohol-use as another representation of health-related behaviour; exercise did not contribute significant confounding in a previous study (6) . We did not examine BASMI, ESR or CRP as these variables required a clinic visit, which made them distinct from questionnaire-derived variables that would require separate modelling. ESR/CRP were also different in that they were measured only when clinically indicated.
Subtle differences between smoking status for some outcomes were not clinically important and should not be over-interpreted. It was interesting that current and ex-smokers had non-significantly greater improvement in analysis 1, which may be explained by regression towards the mean. Higher
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Results from three similar studies are summarised in table 4. The first, by Ciurea et al., used mixed models to show a statistically significant, but not clinically important, effect of smoking only among a subgroup of those with elevated baseline CRP (6) . Their "step model" of initial response was analogous to analysis 1 in our study. The main difference was that patients needed to have at least one follow-up to be eligible. Conditioning on follow-up attendance is likely to introduce bias (29).
The study by Kydd et al. used linear mixed models to include individuals with only one data-point:
the maximum number of patients at any assessment period was 252 despite a total sample size of 422. Only 99 patients had their outcomes of interest assessed before initiating TNFi, therefore making it difficult to adjust for baseline differences. In that study, the interaction terms, representing the difference in outcomes between smoking status, were not significant.
Previous studies that used binary definitions of response reported dramatic effect sizes related to current smoking (6, 7) . The study by Ciurea et al., which found no clinically meaningful overall difference in continuous BASDAI according to smoking status, reported 46% reduced odds for achieving BASDAI50 response (OR 0.54; 95%CI 0.31 to 0.95) at 1 year (±6 months) (6) . This was reproduced by Glintborg et al. using BASDAI50/2 at 3 and 6 months (7) . Small changes in continuous outcomes should not translate to significant differences in the proportion of responders when they are dichotomised. There are two potential explanations. If all patients had identical improvements in BASDAI, smokers would still have poorer BASDAI50 response because of their higher baseline BASDAI. Hypothetically, if each participant in our cohort improved by an identical 3 units, their BASDAI50 responses at 6 months would be significantly different (40%, 35% and 28% for never, exand current smokers, respectively). Second, patients who discontinued treatment were labelled as non-responders. Whether smoking has a biological effect on response is a different question to whether it increases treatment discontinuation, yet this distinction is crucial for causal inference.
Smokers may discontinue treatment for reasons other than inefficacy that may be confounded by, for instance, attitudes to health. While binary responses can be helpful in including dropout due to inefficacy, other reasons for dropout should be modelled separately. In the current study, smoking did not affect BASDAI50/2 when we separately accounted for subjects who were censored for reasons other than inefficacy. These negative results were supported by a post hoc analysis of the ABILITY-1 randomised clinical trial, where smoking status did not affect binary response or time to response (5) .
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Conclusion
We used this analysis to highlight methodological considerations for future observational studies aiming to explore causal effects of exposures on treatment response. In this large UK cohort of axSpA participants, response to the first TNFi did not differ significantly according to baseline smoking status. Prescribers should dispel any subconscious bias that smokers may not respond as well to treatment. Nevertheless, we emphasise the importance of smoking cessation, particularly given the high burden of cardiovascular disease in rheumatic patients (30, 31) . Smoking is associated with more severe disease (activity, functional impairment and radiographic progression (32)); it is not known whether cessation leads to improvement in disease outcome. 
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This article is protected by copyright. All rights reserved. categorical variables. + Not all variables had complete data, HLA-B27 status was available for 468 participants, ASDAS for 539. *Above upper normal limit. **Non-parametric test for trend across ordered groups. SD, standard deviation; IQR, interquartile range; mNY, modified New York criteria for Ankylosing Spondylitis; BMI, body mass index; BASDAI, Bath AS disease activity index; ASDAS, AS disease activity score; BASFI, Bath AS functional index; ASQoL, AS quality of life questionnaire; BASG, Bath AS Global Score; HADS, Hospital Anxiety and Depression Scale. 
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